Hair and Scalp Dermatology

Hair Loss Treatment in Seoul

Hair loss treatment at Delight Dermatology in Gangnam is diagnosis-first, built on FDA-approved Finasteride and topical Minoxidil for androgenetic alopecia. Hair loss responds to different treatments depending on whether it is androgenetic, telogen-effluvium-driven, inflammatory, or scarring — the right combination of drugs, scalp regeneration, and biostimulators is built around that diagnosis, not the other way around.

Board-Certified

Dermatologist

AAD International Fellow

IFAAD

FDA-cleared

Where applicable

MFDS-registered

Korean MoH&W

Reviewed personally by Dr. SangYoul Yun

Board-certified Dermatologist · AAD International Fellow (IFAAD) · IFAAD-verified

Overview

Specialist-led hair loss care in Gangnam by a board-certified dermatologist. Drug therapy, scalp regeneration injections, and biostimulator protocols are sequenced after diagnosis — not as a one-size-fits-all package.

Best for

androgenetic alopecia (male-pattern / female-pattern hair loss)
telogen effluvium (post-stress / postpartum diffuse shedding)
early thinning at the hairline or crown
scalp inflammation or seborrheic conditions contributing to shedding
patients who have tried over-the-counter minoxidil without sustained result

Suited for

patients wanting a diagnosis-first plan rather than a single-modality program
patients with prescription appetite (oral Finasteride / Dutasteride / Spironolactone)
patients seeking scalp-injection regenerative care alongside drugs
international patients combining diagnosis and a starter program in one visit

Duration: 30-60 min (consultation + scalp injection visit)
Sessions: Drug therapy daily; PRP × 3 at 4-week intervals, then every 3-6 months
Downtime: Minimal (mild scalp tenderness 24-48 h after injection)
Peak result: 6-12 months for visible density change

Timeline

First 4 weeks
Drug therapy initiated. PRP first session typically performed at the diagnostic visit if appropriate. No visible density change yet — this period is for tolerance and side-effect monitoring.
3 months
Drug therapy: measurable reduction in shedding for most responders. PRP: completion of 3-session loading protocol; early follicle response.
4-6 months
PRP: hairline thickening often visible at the 4-6 month mark with the standard 3-session protocol.
6-12 months
Drug therapy: visible density change for most responders; trajectory established. Maintenance plan adjusted with the dermatologist.
12+ months
Long-term maintenance — drug therapy continued, PRP every 3-6 months when indicated, adjuncts (Botox / exosome / stem cell) sequenced as the diagnosis evolves.

Devices

Drug therapy — Finasteride / Dutasteride / Minoxidil / Spironolactone

Multiple manufacturers (oral and topical formulations)Finasteride 1 mg: U.S. FDA-approved for male AGA (1997). Dutasteride 0.5 mg: South Korea MFDS-approved for male AGA (2009). Minoxidil 2%/5% topical: U.S. FDA-approved for AGA. Oral low-dose Minoxidil and Spironolactone: prescribed off-label with established dermatology evidence.

Key specs

: Finasteride 1 mg oral, daily — selective 5α-reductase type II inhibitor; reduces scalp DHT and slows miniaturisation in androgenetic alopecia. Strong RCT evidence (Kaufman 1998).
: Dutasteride 0.5 mg oral, daily — dual 5α-reductase inhibitor (types I + II) with greater DHT suppression; useful when Finasteride alone is insufficient.
: Minoxidil — topical 5% solution or low-dose oral (0.25-2.5 mg/day, off-label); vasodilator with proposed potassium-channel-opener mechanism.
: Spironolactone — oral, used for female pattern hair loss as an anti-androgen alternative to Finasteride.
: Side-effect profile, bloodwork (ferritin / thyroid / hormone panel where relevant), and follow-up at 3 and 6 months are reviewed at consultation.

Skin Botox — scalp / hairline injection

Botulinum toxin type A (multiple manufacturers)Used off-label for AGA; small-trial evidence (Singh 2017) — adjunct, not primary.

Key specs

: Low-dose botulinum toxin distributed across the scalp.
Proposed mechanism: reduce scalp tension and increase blood flow to follicles.
: Evidence base is smaller than for drug therapy; positioned as an adjunct.
: Generally well tolerated in published pilot studies.

Exosome scalp application

Multiple stem-cell-derived exosome preparationsAdjunct use; evidence is early-stage. Not a substitute for drug therapy.

Key specs

: Extracellular vesicles derived from stem cell culture media.
: Carry signaling molecules (microRNA, growth factors) that may influence follicle stem cell activity.
: Applied topically after microchannel creation (microneedling / fractional laser).
Honest positioning: adjunct, not standalone.

Stem cell scalp injection

Stem-cell-derived preparations (multiple sources)Adjunct use; evidence base smaller and more heterogeneous than drugs or PRP. Indications include androgenetic alopecia and scarring alopecia.

Key specs

: Injected into the scalp to create an environment that supports follicle self-regeneration.
Standard interval: every 3-6 months per session.
: Indications include androgenetic alopecia and scarring alopecia (cicatricial alopecia).
: Useful as part of a combination plan, not as a replacement for proven drug therapy.
: Sequencing and candidacy determined by dermatologist after diagnosis.

PRP scalp injection

Patient-derived autologous platelet-rich plasmaMultiple RCTs and meta-analysis evidence for modest improvement in AGA (Gupta & Carviel 2017 meta-analysis).

Key specs

: Patient's own blood centrifuged to concentrate platelets and growth factors.
: Injected into the scalp at standardised depths.
Typical protocol: 3 sessions at 4-week intervals, then maintenance every 3-6 months.
: Strongest published evidence among the in-clinic regenerative options for androgenetic alopecia.

Process

01
Hair pull test, dermoscopy, and pattern review classify the hair loss type (androgenetic vs telogen vs inflammatory vs scarring).
02
Bloodwork is ordered when relevant (ferritin, thyroid, hormone panel) before prescribing systemic therapy.
03
Drug therapy options are explained — Finasteride, Dutasteride, Minoxidil, and Spironolactone each suit different patterns and patient profiles.
04
In-clinic options — scalp Botox, exosome topical, stem-cell scalp injection, and PRP — are sequenced based on diagnosis, not bundled.
05
Long-term plan is structured: most patients need a 6-12 month commitment for a measurable trajectory change.

“Injectables and energy devices are performed by physicians — never delegated to non-physician staff. The clinic is led by a board-certified dermatologist.”
— Dr. SangYoul Yun · Clinic Director · Board-Certified Dermatologist · AAD IFAAD

Aftercare

First 24-48 hours after scalp injection
Avoid vigorous scalp scrubbing, hot showers, saunas, and heavy sweating. Mild tenderness or pinpoint redness at injection sites is normal.
Week 1
Resume gentle shampooing the day after the procedure. Avoid alcohol-based scalp tonics and aggressive styling products on injection days.
Drug therapy — ongoing
Take oral medication as prescribed. Report any concerning side effects between visits. Bloodwork follow-up at 3 and 6 months when relevant.
Long-term
Hair outcomes are cumulative. Treat 6-12 months as the minimum window before re-evaluating the plan. Photographic tracking at each follow-up visit makes the trajectory visible.

FAQ

Will one treatment cure my hair loss?

No single treatment cures all hair loss. The dermatologist classifies your hair loss type during consultation, then selects the appropriate combination — drugs, scalp injections, or biostimulators — based on what is actually causing the loss.

Are oral Finasteride and Dutasteride safe?

Both are well studied with extensive long-term safety data. Side effects exist and are reviewed in detail during consultation. Bloodwork is ordered when relevant before prescription, and follow-up is scheduled at 3 and 6 months.

How long until I see results?

Hair grows slowly. Drug therapy typically shows a measurable change in shedding by 3 months and visible density change by 6-12 months. PRP often shows hairline thickening at the 4-6 month mark with the standard 3-session protocol.

Should I do PRP, exosomes, or stem cell injection?

These three are not interchangeable. PRP has the strongest published evidence for androgenetic alopecia. Exosomes and stem cell injection are newer and used as adjuncts. Your dermatologist will sequence them based on diagnosis and treatment goal — not as a fixed package.

Can I start treatment during a short visit to Seoul?

Yes. Diagnosis, prescription, and a first PRP or scalp injection can typically be completed in a single visit. Drug therapy continues in your home country with follow-up via teleconsultation as needed.

Notice

Tell the dermatologist at consultation if any of the following apply.

Pregnancy and breastfeeding (Finasteride, Dutasteride, Spironolactone contraindicated; PRP and most adjuncts deferred)
Active scalp infection or open wounds in the injection field
Bleeding disorders or active anticoagulation without physician clearance (PRP / scalp injections)
Known hypersensitivity to any prescribed medication or component
History of breast or hormone-sensitive cancer — dermatologist review required before anti-androgen therapy

For your visit

Diagnosis, prescription, and a first PRP or scalp injection can typically be completed in a single visit.
Drug therapy continues in your home country with follow-up via teleconsultation as needed.
Bring any prior diagnosis, medication history, or scalp treatment details if possible.

References

The clinical claims on this page — device specs, efficacy timelines, safety profile — are supported by the primary sources below. Each citation links to the original paper or regulatory record.4 refs

[1]Finasteride in the treatment of men with androgenetic alopecia (Finasteride Male Pattern Hair Loss Study Group). J Am Acad Dermatol (Kaufman et al.) (1998).
[2]Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol (Sinclair RD) (2018).
[3]A Pilot Study to Evaluate Effectiveness of Botulinum Toxin in Treatment of Androgenetic Alopecia in Males. J Cutan Aesthet Surg (Singh et al.) (2017).
[4]Meta-analysis of efficacy of platelet-rich plasma therapy for androgenetic alopecia. J Dermatolog Treat (Gupta & Carviel) (2017).

Reviewed byDr. SangYoul Yun· Board-Certified Dermatologist · AAD International Fellow (IFAAD)· Last reviewed 2026-05-05

Related procedures

ProcedureExosome Therapy — Educational Overview (Not Offered at Delight)Educational overview of exosome therapy — what the evidence supports, regulatory status, and why we do not currently offer this modality at Delight Dermatology.

Notice: Individual results may vary depending on skin condition, treatment history, and recovery factors. All treatment plans are determined through individual consultation with a board-certified dermatologist. The information on this page is for reference only and does not constitute medical advice or guarantee specific outcomes.

Next Step

You can start with a short message before deciding on Hair Loss Treatment.

Even a short first message can help you check suitability, timing, and what to compare next before you book.

Contact

WhatsApp LINE KakaoTalk